Last reviewed · How we verify

NCT05509270

Efficacy of Communication Modalities for Promoting Flu Shots

Completed NA Last updated 12 October 2022
What this trial tests

NA trial testing Letter in Influenza Vaccination in 43,225 participants. Completed in 4 October 2022.

Timeline
6 September 2022
Primary endpoint
4 October 2022
4 October 2022

Quick facts

Lead sponsorGeisinger Clinic
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment43,225
Start date6 September 2022
Primary completion4 October 2022
Estimated completion4 October 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Geisinger Clinic

Who can join

18 and older, any sex, with Influenza Vaccination or Health Promotion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test which modalities (mailed letter, short message service \[SMS\] text, or patient portal messages) are most effective for encouraging flu shots in high-risk patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Letter

Trials testing the same drug.

Other recruiting trials for Influenza Vaccination

Currently open trials in the same condition.

Other Geisinger Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05509270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing